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Alzheimer’s disease (AD) is the most common cause of dementia in the world. AD is 
characterized pathologically by the presence of Amyloid-β (Aβ) plaques and tau neurofibrillary 
tangles (NFTs). Advanced glycation endproducts (AGEs), which are derived from alpha-
dicarbonyls such as methylglyoxal (MG), form endogenously with physiological aging. These 
AGEs have been observed to co-localize with both the plaques and NFTs in AD patients’ brains.  
Receptor for advanced glycation endproducts (RAGE) has been implicated in the 
pathogenesis of AD. However, the exact mechanism by which RAGE contributes to AD pathology 
is only partially known. Glyoxalase-1(GLO1) is an important enzyme involved in the 
detoxification of precursors of AGEs, which serve as the highly reactive primary ligands for 
RAGE. GLO1 is found to be downregulated in the brains of advanced stage AD patients whereas 
RAGE is overexpressed in such brains. 
Aging is associated with increased generation and deposition of AGEs, resulting from non-
enzymatic glycation (or oxidation) of proteins and lipids. Higher AGE formation is associated with 
a multitude of cellular and synaptic disturbances. Thus, to see the direct effect of age on enzyme 
activity, we first performed a study of wild type (WT) animals from 3 to 30 months and found that 
beyond 12 months of age, GLO1 activity significantly decreases. This shows that aging can be a 
major factor contributing to AD pathology through the downregulation of GLO1 activity. For 
uniformity, we used 12 months old mice for all further studies.  
In order to investigate whether RAGE directly modulates GLO1 enzyme activity and 
protein expression, we used previously generated multiple transgenic (Tg) non-AD mouse models 




dominant-negative mutant RAGE (DNRAGE). They were, in the past, characterized for RAGE 
and subsequent RAGE-mediated signal transduction in our lab. GLO1 enzyme activity was 
measured spectrophotometrically while GLO1 protein expression was determined with western 
blotting. 
The Tg mice displayed either a) an increase in GLO1 enzyme activity, and/or b) an increase 
in GLO1 protein expression when compared with age-matched WT controls. Global RAGE 
knockout (RO) and neuronal RAGE knockout (nRKO) mice showed significantly higher GLO1 
enzyme activity compared to WT controls. RO mice showed a significant increase in the protein 
expression but nRKO mice did not. Similarly, the mice with DNRAGE targeted to cortical neurons 
(neuronal DNRAGE) and to microglia (DNMSR) exhibited an increase in GLO1 enzyme activity 
compared with WT mice but showed no significant change in protein expression. This differential 
effect in protein expression can be due to the difference in post-translational modification such as 
disulfide bridge formation or presence of GLO1 variations. It could also be the effect of normal or 
higher GLO1 activity in non-neuronal or microglial cells. 
Given the clear modulation of GLO1 by RAGE variation, we performed the GLO1 enzyme 
activity and expression assays in Tg mice modeling amyloid plaque development by expressing a 
mutant form of human APP leading to overproduction of Aβ (mAPP) to see if similar effects are 
observed in a mouse model showing AD-like pathology. We also crossed these mAPP mice with 
RO mice to develop RAGE-deficient mAPP mice (mAPP/RO). The mAPP mice showed a 
significant reduction in both GLO1 enzyme activity and protein expression. mAPP/RO mice and 
RO mice showed higher GLO1 activity and protein expression compared to mAPP mice. These 




deletion of RAGE protects against this decrease. Also, it supports the hypothesis that loss of 
RAGE-mediated signaling leads to an increase in GLO1 activity, whereas specific APP mutation 
(and Aβ overproduction) contributes to the decrease in GLO1 activity.  
Taken together, these data show that RAGE functions as an active modulator of GLO1 
enzyme activity, thereby providing new insights into a mechanism by which the RAGE-dependent 
signaling cascade contributes to the pathogenesis of AD. Thus, RAGE deletion or blockade of 
RAGE signaling may be a potential target for developing treatments for preventing the progression 
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Alzheimer’s disease (AD) is a progressive, and irreversible neurodegenerative disorder. It is 
characterized by memory loss, personality changes, and cognitive impairment and affects 1 in 10 
people of ages 65 or older, making it the most common form of dementia in older adults [1-6]. It 
is predicted to affect approximately 42 million people worldwide by the year 2020[7]. The main 
pathological features of AD are the formation of amyloid-β (Aβ) deposits in the anterior cerebral 
cortex and hippocampus as well as the formation of intracellular neurofibrillary tangles (NFTs) 
resulting in neuronal cell death [3, 5, 8-11]. Aβ, which is a 40–42 amino-acid peptide generated 
by proteolytic cleavage of the amyloid precursor protein (APP), and NFTs, which are composed 
of a hyper-phosphorylated microtubule-associated tau(τ) protein, are the major markers of 
progression of AD [3, 5, 6, 11-22]. 
 
ADVANCED GLYCATION ENDPRODUCTS (AGEs) 
 
Advanced glycation endproducts (AGEs) are members of a heterogeneous class of molecules, 
which modify cellular function by distinct mechanisms including ligation and activation of signal 
transduction receptors. These AGEs are the products of non-enzymatic glycation (or oxidation) of 
proteins and lipids. The levels of AGEs increase during biological aging due to decreased 
efficiency of homeostatic processes. AGEs also further contribute to the normal physiological 
aging process [22, 23]. When their production is accelerated, they have a causative role in the 




Parkinson’s, and Huntington’s diseases [22, 24-27]. Excess AGE accumulation is detrimental to 
neurons and is believed to be a key to the pathogenesis of cognitive decline in normal aging and 
specific chronic diseases of aging [28-31]. 
 
Long-lived proteins such as Aβ and hyper-phosphorylated tau that accumulate in AD brain are 
highly susceptible to AGE modification. AGE modified Aβ or tau protein result in increased 
oxidative stress and chronic inflammation, accelerating AD pathology and neuronal perturbation 
[32-40]. Moreover, Aβ or tau glycation results in increased aggregation and subsequent formation 
of senile plaques or NFTs, the major pathological feature of AD suggesting that AGE modification 
is an important risk factor for AD[24, 41-47]. Although increased accumulation of AGEs in brain, 
as seen in aging, diabetes, or neurodegenerative diseases, speeds up oxidative damage to neurons 
contributing to synaptic dysfunction and cognitive decline, the underlying  mechanisms for this 
accumulation  are not well understood [48]. 
 
These AGEs, formed by non-enzymatic glycation of proteins and lipids on exposure to sugars, 
play an important role in normal aging and in degenerative diseases such as AD, atherosclerosis 
and ALS (amyotrophic lateral sclerosis) [24, 47]. Receptor for these AGEs (RAGE) is a multi-
ligand, transmembrane receptor expressed by neurons, microglia, astrocytes, cerebral endothelial 
cells, pericytes, phagocytes, cardiac myocytes, hepatocytes, and smooth muscle cells [49]. Increase 
in the expression of RAGE is seen in AD-affected brain regions [50-52]. RAGE and its isoforms 
play an important role in the regulation of metabolism, inflammation, and epithelial survival in 





In addition to AGEs’ ability to directly alter the structure and function of targeted proteins within 
cells that causes cell or tissue damage, emerging evidence has also demonstrated AGEs as a 
signaling ligand, interacting with RAGE[22, 56-60]. AGEs elicit signal transduction changes that 
adversely affect numerous peripheral organs. Although AGE accumulation is increased in cortical 
neurons, hippocampal pyramidal neurons, astrocytes, and other glial cells in aging and AD 
brain[14, 45, 56, 59, 61, 62], the direct effect of AGEs–RAGE interaction on brain function, and 




RAGE was first identified as a cell surface receptor of the immunoglobulin superfamily for AGEs 
[5, 63-68]. There are three major isoforms of RAGE.  These different RAGE isoforms are 
generated as the result of alternative splicing and are defined as being the full-length RAGE, 
dominant negative RAGE (DNRAGE), and secretory RAGE (sRAGE) [53, 54, 68].  Increased 
expression of RAGE occurs in neuronal and non-neuronal cells in the peripheral and central 
nervous system in aging, diabetes, and AD affected individuals, where RAGE ligands are 






RAGE and microglia 
 
RAGE-dependent signaling in microglia contributes to neuroinflammation especially in mouse 
models of AD that ultimately impairs neuronal function and directly affects amyloid accumulation 
[74, 75].  Deposition of cross-linked insoluble protein aggregates such as amyloid plaques is 
characteristic for Alzheimer’s disease. Microglial activation by these extracellular deposits has 
been proposed to play a crucial role in functional degeneration as well as neuronal cell death[76]. 
AGEs activate specific signal transduction pathways, resulting in the up-regulation of various 
proinflammatory signals such as cytokines [interleukin-6 (IL-6), tumor necrosis factor-alpha 
(TNF-a)] and nitric oxide synthase (NOS)[77] . The blockade of microglial RAGE (by using 
Cre/loxP technology) is found to have beneficial effect on Aβ-mediated neuronal changes relevant 
to AD pathogenesis [3, 10, 63, 64, 73, 74, 78-80]. 
 
RAGE and neuronal function 
 
Genetic deficiency of neuronal RAGE protects against AGE-induced synaptic injury. RAGE and 
nuclear factor kappa B (NF-қB) have been related to neuronal death [81]. Interaction of Aβ with 
neuronal RAGE leads to NF-қB activation, indicating a possible role of neuronal RAGE in 
inflammation[72]. Aβ induces a RAGE-dependent pathway that involves activation of p38 MAPK, 
resulting in Aβ internalization and leads to mitochondrial dysfunction in cortical neurons[82]. 
RAGE blockade can be a target for development of interventions aimed at preventing progression 







Methylglyoxal (MG) is a highly reactive dicarbonyl compound formed in vivo as a major 
byproduct of glycolysis. MG is an endogenous byproduct of the normal metabolism of 
carbohydrates along with lipids, and proteins, inevitably produced spontaneously or enzymatically 
[86, 87]. 
 
During glycolysis, MG is readily formed under alkaline conditions from glyceraldehyde or 
dihydroxyacetone[88]. Intermediate metabolites such as acetoacetate from lipids, and succinyl 
acetone and amino acetone from threonine and glycine metabolism, are also endogenous sources 
of MG . Accumulation of MG is highly toxic, since it readily reacts in vivo with basic 
phospholipids and nucleotides, and with lysine and arginine residues of proteins, leading to AGE 
formation [89-92]. MG can also impair the antioxidant system by depleting glutathione (GSH) 
levels[87]. It has been considered as a possible causative agent in a number of pathologies, such 
as diabetes [93, 94], hyperalgesia and inflammation, aging disorders[5, 59], Alzheimer’s 
disease[95, 96], epilepsy, autism[97], and anxiety[98, 99] among others. 
 
MG concentration in human plasma is in the range of 0.1–0.6 μM, and about 10- to 20 fold higher 
in the cerebrospinal fluid [100-102]. These elevated levels of MG can make nerve cells more 
susceptible to AGE formation, which is thought to be a relevant factor in the development of 
neurodegenerative diseases[103]. MG can induce irreversible loss of protein function, including 




formation of AGEs. Under normal physiological conditions, MG is detoxified by the glyoxalase 
system to give D-lactate, with GLO1 as the key rate-limiting enzyme in the process [86]. 
 
GLYOXALASE-1 (GLO1)  
 
AGE precursor compounds are cellularly detoxified by the glyoxalase system, consisting of GLO1 
and 2. GLO1 is a cytosolic enzyme which catalyzes the isomerization of hemithioacetal adducts, 
formed in a spontaneous reaction between a glutathionyl group (such as GSH) and aldehydes (such 
as MG). Since alpha-oxoaldehydes, such as MG are important intracellular AGE precursors [105], 
GLO1 has an important role in reducing cellular AGE levels. Binding of AGEs to RAGE causes 
suppression of GSH thus increasing the intracellular oxidative stress[60, 106]. Decrease in GSH 
leads to decreased GLO1 activity [107]. Also, decrease in GLO1 activity due to aging and 
oxidative stress results in increased glycation and tissue damage. In vitro studies with endothelial 
cell lines have shown that GLO1 over-expression prevents intracellular AGE formation [108]. 
GLO1 levels are diminished in brains of older adults and in AD patients’ brains. However, the 
mechanism behind the change is still unknown. Understanding this mechanism of modulation will 
help in precise targeting of GLO1 for treatment of AD. [23, 46, 86, 90, 91, 93, 94, 98-100, 107-
145] 
 
As high levels of AGEs are involved in GLO1 downregulation, we hypothesized that RAGE 
decreases GLO1 activity in transgenic non-AD (RAGE knockout and DNRAGE) and AD (mAPP) 




1. effect of physiological aging 2. effect of RAGE deletion or signaling blockade and 3. effect of 
mutant APP on GLO1 enzyme activity and protein expression. 
 
As RAGE is expressed in neurons and non-neuronal cells (i.e., glial, endothelial cells, and 
pericytes of the blood–brain barrier) [48], the results obtained from global RAGE knockout(RO) 
mice do not explain which cell types are important in AGE-induced impairments. Therefore, study 
of transgenic mice with neuronal RAGE knockout (nRKO) and DNRAGE mutant specifically in 
the microglia and neurons was done[28, 48, 146], to address the question of whether the activities 
of neuronal and microglial RAGE are responsible for AGE-induced GLO1 reduction [48]. 
 
The purpose of this thesis is to investigate the link between GLO1 activity and protein levels and 






MATERIALS & METHODS 
 
ANIMALS 
Generation and characterization of global knockout of RAGE mice 
For our experiments, transgenic (Tg) RO mice generated previously were used. Homozygous 
RAGE null mice (generated in the 129 strain) were backcrossed three generations into C57BL/6; 
mating of heterozygous RAGE null males and females yielded heterozygous mice, as well as wild-
type RAGE-bearing (RAGE+/+) and homozygous RAGE null animals (RAGE–/–). RAGE null mice 
are viable and display normal reproductive fitness [66]. In all cases, age-matched littermates (WT-
wild type) were employed as controls. The mice were characterized for RAGE and signaling 
markers in our lab. The institutional Animal Care and Use Committee of the University of Kansas 
approved all protocols. 
 
Generation and characterization of conditional neuronal knockout of RAGE mice 
Previously generated nRKO mice were used for experiments. Our lab developed a model system 
in which neuronal expression of RAGE, in particular in the brain region responsible for learning 
and memory, is deleted so that consequences of receptor–ligand interaction could be assessed 
[48]. To this end, Cre recombinase neuronal RAGE null mice, termed as Tg nRKO mice were 
created by crossing neuronal-targeted and region-restricted Tg mice that express Cre 
recombinase in the entire forebrain, under the control of the forebrain-specific calcium-
calmodulin-dependent kinase II (CAMKIIA, CK2) promoter to generate deletion of neuronal 
RAGE in the entire hippocampus and cortex. Cre-loxP system was used to generate the targeting 




The targeting vector consists of three fragments: the 5′ homology arm, the 3′ homology arm, 
and loxP arm. Two loxP sites flanking RAGE exons 2–4 allow for Cre-mediated deletion using 
Cre recombinase. Excision of exons 2–4 by Cre recombinase results in a frame shift and early 
stop codon from the mouse RAGE sequence, which block RAGE expression. Our lab first made 
homozygous RAGE floxed allele mice (RAGE flox/flox); then RAGEflox/floxmice were crossed with 
neuronal target CK2 mice to generate homozygous floxed and hemizygous Cre nRKO mice 
(RAGEflox/flox/CK2-Cre), which were then verified by analysis of tail DNA with PCR 
amplification using primers for flox (700 bp) and Cre transgene (300 bp). Immunoblotting of 
cortical homogenates with anti-RAGE antibody showed significant reduction of RAGE 
expression levels in cerebral cortex of nRKO mice compared with non-Tg mice (∼80% 
reduction versus non-Tg brain, P<0.01). The observed incomplete suppression of RAGE 
expression was due to the use of brain homogenates, which contained non-neuronal cells with 
intact RAGE. Confocal microscopy with double immunostaining of RAGE and MAP2(neuron 
specific protein marker) clearly demonstrated that there was virtually no RAGE signal in 
MAP2-positive neurons in cortex and hippocampus of nRKO mice, thereby verifying RAGE 





Generation and characterization of transgenic mice with cytosolic dominant-negative RAGE 
(neuronal DNRAGE) 
Previously generated neuronal DNRAGE mice were used for the experiments. We used the 
transgenic mice with signal-transduction-deficient mutants of RAGE in which the cytosolic 
domain of the receptor was deleted, thereby imparting a dominant-negative (DN)-RAGE effect, 
targeted to neurons (neuronal DNRAGE) driven by the platelet-derived growth factor-B (PDGF-
B) chain promoter [66, 72]. These neuronal DNRAGE mice were characterized, demonstrating 
localization of DNRAGE in cortical neurons previously in our lab. 
 
Generation of transgenic mice with Dominant-negative effect targeted to microglia 
(DNMSR-microglial DNRAGE) 
Previously generated transgenic mice with signal-transduction-deficient mutants of RAGE in 
which the cytosolic domain of the receptor has been deleted, thereby imparting a dominant-
negative RAGE effect, targeted to microglia (DNMSR) driven by the macrophage scavenger 
receptor (MSR) type A promoter, were used for this study[20, 75, 80]. Founders were identified 
by mouse tail biopsy; DNA was prepared, and Southern blot was performed using human RAGE 
cDNA as a probe and by PCR. Mice were generated and hemizygous mice backcrossed eight 
generations into C57BL/6 were used in our studies. Human DNRAGE transgene was identified 
by PCR using primers 4A-5’AGGATCAGGGCTGGGAACTCTA, and  






Generation of transgenic mAPP AND mAPP/RO mice [28] 
Previously generated transgenic mice with neuronal overexpression of a mutant human form of 
APP (Tg mAPP or mAPP, J-20 line, Jackson Lab) driven by the PDGF-B chain promoter were 
used in this study[28, 147]. These mAPP mice are a well-established mouse model of AD and 
exhibit many features of AD neuropathology[28, 72], and have been used in previously published 
studies [72, 73, 78, 147-150]. Homozygous RAGE null mice (RO mice) were backcrossed into 
C57BL/6 strain for more than 12 generations and were crossed with mAPP mice to generate 
mAPP/RO mice. Age-matched non-genetically modified WT littermates were used as controls in 
our studies. Mice were maintained on normal rodent chow and allowed free access to food and 
water. Genomic DNA was isolated from tail biopsies and subjected to PCR analysis to identify the 
deficiency of RAGE or human APP gene. The mice were anesthetized with ketamine (100 mg/kg) 
and Xylazine (10 mg/kg) and flush perfused transcardially with 0.9% saline. Brains were removed 
and divided sagittally. One hemibrain was post-fixed in phosphate-buffered 4% paraformaldehyde 
(pH 7.4) at 4oc for 26h and sectioned at 20 mm with a vibratome (Leica); the other hemibrain was 





Details of all animal models used are summarized in the following table: Table 1. 
Table 1: Details of animal models used for experiments 
 








1 RO Global RAGE 
knockout 
- - - 
















4 DNMSR Signal deficient 








5 mAPP Overexpression of 
APP 
+ + + 
6 mAPP/RO APP crossed with 
RO 








GLO1 ENZYME ACTIVITY KINETIC ASSAY 
GLO1 catalyzes the isomerization of the hemithioacetal formed non-enzymatically from MG and 
GSH to S-D-lactoylglutathione. In this assay, the activity of GLO1 was measured 
spectrophotometrically by following the increase in OD240 for which the change in molar 
extinction coefficient Δε240=3.37 mM⁻¹·cm⁻¹. The hemithioacetal was pre-formed in situ by 
incubation of MG and GSH in 50 mM sodium phosphate buffer (0.02 M Sodium phosphate dibasic 
heptahydrate, 0.03 M Sodium phosphate monobasic monohydrate, pH 6.6) at 37°C for 10 min. 
The tissue sample homogenate was then added, the OD240 was monitored over 10 min, and the 
initial rate of increase in OD240 and hence GLO1 activity was deduced with correction for blank. 
GLO1 activity is given in units per mg of protein where one unit is the amount of enzyme that 
catalyzes the formation of 1 μmol of S-D-lactoylglutathione per min under assay conditions.  
 
Calculation of enzyme units 










) (Total volume of assay)(dilution factor)]
[(Extinction Coeff. of S − Lactoylglutathione)(Volume of enzyme used)]
 
 
Where.   Total volume (in milliliters) of assay=0.2 (200 ul reaction) 
                  Millimolar extinction coefficient of S-Lactoylglutathione at 240 nm= 3.37 
              Volume (in milliliter) of enzyme used= 0.0067 (6.7 ul protein samples) 
 
Units/ml enzyme =
(∆A240nm/min Test − ∆A240nm/min Blank)(0.2)(1)
(3.37)(0.0067)
 





Total protein extracts were prepared from the dissected frontal cortical brain from snap-frozen 
hemi-brains by homogenization with 1× RIPA buffer (20 mM Tris-HCl  pH 7.5, 150 mM NaCl, 1 
mM Na2EDTA, 1 mM EGTA,1% NP-40, 1% Sodium deoxycholate, 2.5mM sodium 
pyrophosphate,1 mM Na2VO4, Catalog #9806, Cell Signaling Technology, MA) containing 1× 
protease inhibitor cocktail (104 mM AEBSF, 80 μM Aprotinin, 4 mM Bestatin, 1.4 mM E-64, 2 
mM Leupeptin and 1.5 mM Pepstatin A, Roche applied Science, IN) and 1 mM PMSF 
(Phenylmethylsulphonyl fluoride) OR with 0.01% Triton-X solution in DPBS (Dulbecco’s 
Phosphate-buffered saline, KCl, KH2PO4, NaCl, Na2HPO4.7H2O, Catalog #A14190144, Gibco-
Thermo Fisher Scientific). Total protein extracts from cells were prepared using 1× cell lysis buffer 
(20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5mM 
sodium pyrophosphate,1 mM Na2VO4, Catalog #9803, Cell Signaling Technology, MA) 
containing 1× protease inhibitor cocktail and 1 mM PMSF. Protein concentrations of the tissue or 
cell lysates were spectrophotometrically determined with Bio-Rad protein assay dye reagent 
(acidified Coomassie Brilliant Blue G-250) concentrate kit at 595nm. Equal amount of protein 
from each sample was loaded and then separated by SDS/PAGE (12% Bis–Tris gel, Catalog# 
NP0301, Invitrogen/Thermo Fisher Scientific, Austin, USA), and then electrophoretically 
transferred to 0.45 µm nitrocellulose membranes (Catalog# 162-0094, Bio-Rad Laboratories, 
Hercules, CA, USA) using NuPAGE running buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 
1 mM EDTA, pH 7.3, 50 ml 10 X buffer in 1 L milliQ H2O, Thermo Fisher Scientific, Cat. No. 
NP0002, Lot no. 1958831). Non-specific binding was blocked by 5% non-fat milk in TBS buffer 
(30 ml 5M NaCl and 20 ml 1M Tris-HCl in 1L milliQ H2O, 20 mM Tris–HCl, 150 mM NaCl, pH 




(bovine serum albumin) in TBST (TBS containing 0.1% Tween-20, pH 7.6) overnight with gentle 
shaking at 4 °C.  Primary antibodies used for the reactions were as follows: rabbit anti-GLO1 
(1:3000 Catalog #SC-67351, Santacruz biotechnology) and mouse anti-β-actin (1:5000, Catalog 
#A5316, Sigma, St. Louis, MO, USA). The membrane was washed with TBST and then incubated 
with the corresponding horseradish peroxidase-conjugated secondary antibody: goat anti-rabbit 
IgG or goat anti-mouse (1:10 000, Catalog #A6154 or #A4416, Sigma, St. Louis, MO, USA), for 
1 h with gentle shaking at room temperature to identify sites of binding of each primary antibody. 
Finally, the chemiluminescent signal from immunoreactive band was detected with ECL using an 
enhanced chemiluminescent western blot system (Solution A: Luminol solution, Solution B: 
Peroxide solution, GE Healthcare, NJ). GLO1 protein expression was quantified as ratio of 
intensity of GLO1 band to the intensity of β-Actin band (loading control) immunoreactive bands 
by immunoblotting with anti-GLO1 and anti-β-Actin antibodies. Data from western blot was 







The antibodies used in the experiments are listed in following table: Table 2. 
Table 2: Summary of antibodies used 
 








1 Rabbit polyclonal anti-
glyoxalase-1 antibody 
1:3000 Sc-67351 DO114 Santacruz 
Biotech. 
2 Anti-rabbit IgG (whole 
molecule)–peroxidase 
antibody produced in goat 
1:10000 A6154 SLBV9141 Sigma-
Aldrich 
3 Monoclonal anti-β-actin 
antibody produced in 
mouse 
1:5000 A5316 SLBS6528 Sigma-
Aldrich 
4 Anti-mouse IgG (whole 
molecule)–peroxidase 





5 Rabbit polyclonal anti-
RAGE antibody 








All statistical analyses were conducted using GraphPad Prism 8(GraphPad software Inc., La Jolla, 
CA). Shapiro-Wilk’s test for normality and Brown-Forsythe-Levene test for homogeneity of 
variance were used to determine whether the data met the requirements for a parametric analysis 
of variance. Two-tailed student’s t-test, one-way ANOVA, and two-way ANOVA were used for 
analyses (as indicated in the figure descriptions) followed by Tukey’s or Dunn’s test for post-hoc 
multiple comparisons where required. All results were reported as mean ± S.E.M. *p<0.05 was 






1) Effects of physiological aging on GLO1 activity and protein expression in 3 to 30-month-
old WT mice 
To investigate effect of physiological aging on GLO1 activity, we used WT mice of age: 3-30 
months (n=5/age group). Spectrophotometric measurement of GLO1 enzyme activity revealed 
significantly increased GLO1 activity in the brains of 12 months old WT mice compared with WT 
mice at 3 and 6 months of age (Fig. 1A and C). We also found that beyond the age of 12 months, 
GLO1 activity significantly reduced up to 30 months of age (Fig. 1A and C).  We observed that at 
12 months of age, GLO1 activity increases with increase in total protein concentration (Fig.1B). 
Thus, we found that physiological aging contributes to significant decrease in GLO1 activity 
beyond 12 months. Thus, for uniformity, we used 12 months old mice for further experiments 
(except in case of RO mice). 
 
2) Effects of global RAGE knockout on GLO1 activity and protein expression in 6- and 12-
months old mice 
In view of elevated expression of RAGE and reduced expression of GLO1 correlating to the 
severity of AD, we sought to detect the effect of RAGE on GLO1 activity and protein expression 
levels in RO mice. 6 month and 12-month-old homozygous RO mice were used (n=4-5/ 
genotype/age group).  Spectrophotometric measurement of GLO1 enzyme activity revealed 
significantly increased GLO1 activity in the brains of RO mice compared with WT mice at 6 
months (Fig. 2A) and 12 months of age (Fig. 3A).  For 12- months- old RO mice, immunoblotting 
and quantification of GLO1 protein bands (Fig. 3B and 3C) revealed that the protein levels were 




was not seen in 6 months old mice (Fig. 2B and 2C). Global deletion of RAGE contributes to 
increase in GLO1 activity in 6- and 12-months old mice and expression in 12 months old mice.  
 
3) Effects of neuronal RAGE knockout on GLO1 activity and protein expression in 12-
month old mice 
Since RAGE is expressed in both neuronal and non-neuronal cells, we sought to detect the effect 
of conditional neuronal RAGE deletion on GLO1 activity and protein expression levels in 
homozygous nRKO mice. These nRKO mice were used along with age-matched WT controls. 
Spectrophotometric measurement of GLO1 enzyme activity revealed significantly increased 
GLO1 activity in the brains of nRKO mice compared with WT mice at 12 months of age (Fig. 4A). 
Immunoblotting and quantification of GLO1 protein bands (Fig. 4C) revealed that the protein 
levels were not increased significantly in nRKO mice compared with those of WT mice at 12 
months of age (Fig. 4B and 4C). Unlike 12-months-old RO mice, nRKO mice did not show 
elevated GLO1 protein levels. This effect can be attributed to the specific cell types in which 
RAGE knockout was carried out. Here, we found that neuronal deletion of RAGE significantly 
contributes to increase in GLO1 activity but not protein expression. 
 
4) Effects of neuronal DNRAGE mutant on GLO1 activity and protein expression in 12-
month old mice 
Since we found that RAGE deletion leads to increase in GLO1 activity and protein expression, we 
wanted to investigate the effect of neuronal DNRAGE on GLO1 activity and protein expression 
levels. Heterozygous neuronal DNRAGE (n=3-6/ genotype) mice were used along with age-




significantly increased GLO1 activity in the brains of neuronal DNRAGE mice compared with 
WT mice at 12 months of age (Fig. 5A). Immunoblotting and quantification of GLO1 protein 
bands (Fig. 5B) revealed that the protein levels were not increased significantly in these mice 
compared with those of WT mice at 12 months of age (Fig. 5C). This pointed out the need to repeat 
the study in a higher number of experimental mice to confirm the results. Thus, we found that loss 
of signaling of neuronal RAGE significantly elevates GLO1 activity but not protein expression. 
 
5) Effects of microglial DNMSR mutant on GLO1 activity and protein expression in 12 
months old mice 
As microglia have been implicated in the possible pathway of effect of RAGE in AD progression, 
we wanted to investigate the effect of microglial DNMSR mutant on GLO1 activity and protein 
expression levels. Heterozygous DNMSR (n=4/ genotype) mice were used along with age-
matched WT controls. Spectrophotometric measurement of GLO1 enzyme activity revealed 
significantly increased GLO1 activity in the brains of microglial DNRAGE mice compared with 
WT mice at 12 months of age (Fig. 6A). Immunoblotting and quantification of GLO1 protein 
bands (Fig. 6B) revealed that the protein levels were not significantly increased in these mice 
compared with those of WT mice at 12 months of age (Fig. 6C). Thus, we found that loss of 






6) Effects of mutant APP overexpression on GLO1 activity and protein expression in 12 
months old mice 
 
After checking the GLO1 activity and expression in the RAGE knockout and DNRAGE mouse 
models, we then determined whether RAGE had a direct role in modulating GLO1 activity and 
expression in mAPP mice overexpressing mutant APP/Aβ and the effect of deletion of RAGE in 
these mice.  
Homozygous RAGE null mice (RO mice) were crossed with mAPP mice overexpressing mutant 
APP/Aβ to generate mAPP/RO mice (n=5/ genotype). We demonstrated that GLO1 activity and 
protein levels were significantly reduced in mAPP mice compared with WT mice. In contrast, 
GLO1 activity was found to be higher in both heterozygous mAPP/RO and homozygous RO mice 
due to global genetic deletion of RAGE (Fig. 7A). 
Consistent with the enzyme activity results, immunoblotting and quantification of GLO1 protein 
bands (Fig. 7B and 7C) revealed that the protein levels were increased in both mAPP/RO and RO 
mice compared with those of mAPP mice at 12 months of age. Thus, global deletion of RAGE in 
mAPP/RO mice rescues the decrease in GLO1 activity and expression seen in mAPP mice. 
In summary, we provide substantial evidence of the protective effect of deletion of RAGE or loss 
of RAGE signaling on GLO1 enzyme activity. Genetic deletion of RAGE and blocked RAGE 
signaling in cortical neurons or microglia blocks AGE-mediated downregulation of GLO1 enzyme 
activity.  




Table 3: Summary of GLO1 activity and expression in various mouse models compared to 
WT 




1 RO Global RAGE knockout Increased Increased 
2 nRKO Neuronal RAGE knockout Increased Unchanged 
3 Neuronal 
DNRAGE 
Signal deficient mutant targeted to 
neurons 
Increased Unchanged 
4 DNMSR Signal deficient mutant targeted to 
microglia 
Increased Unchanged 
5 mAPP Overexpression of APP Decreased Decreased 



































































































Figure 1: Effect of age on GLO1 enzyme activity in 3 to 30 months old WT mice. 
(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 3 to 
30-month-old WT mice (n=5/group) in an age-dependent manner at three different total protein 
concentrations [Two-way ANOVA with Tukey’s post hoc multiple comparison tests, age: F (3, 
12) = 38.12, concentration: F (2, 3) = 114.2 interaction: F (8, 12) = 13.57, p<0.001].  (B) 
Comparison of GLO1 activity at total protein concentration=2.5 and 5 ug at the age of 12 months 
(student’s t test) (C)GLO1 activity of 3-30-month-old mice at total protein concentration=5 ug. 
(One-way ANOVA with Tukey’s post hoc multiple comparison tests, F (4, 10) = 225.7 P<0.0001    
























































































































Figure 2: Effect of global RAGE knockout on GLO1 enzyme activity and protein expression 
in 6 months old WT and RO mice.  
(A) GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 6-
month-old WT and RAGE Knockout (RO) mice (n=4/ genotype) at total protein concentration= 
5ug and (B) at increasing total protein concentration levels (Two-way ANOVA-  concentration: F 
(3, 8) = 182.1, genotype: F (1, 8) = 246.1, p<0.0001, interaction: F (3, 8) = 7.690, P=0.0096). (C) 
GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands of 
GLO1 in the brain homogenates from indicated mice. (n=4/group). Representative immunoblots 
show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as loading control. 










































































Figure 3: Effect of global RAGE knockout on GLO1 enzyme activity and protein expression 
in 12 months old WT and RO mice.  
(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-
month-old WT and RAGE Knockout (RO) mice (n=5/group) in a time-dependent manner. [Two-
way ANOVA with Tukey’s post hoc test, time: F (4, 40) = 1.235, genotype: F (1, 40) = 140.2, 
interaction: F (4, 40) = 2.1335, P<0.0001)] (B)GLO1 protein expression was demonstrated by 
quantifying intensity of immunoreactive bands of GLO1 in the brain homogenates from indicated 
mice. (n=4-5/group). Representative immunoblots show immunoreactive bands for GLO1(21kda) 
as well as β-Actin protein used as loading control. (C) Quantification of GLO1 immunoreactive 












































































Figure 4: Effect of neuronal RAGE knockout on GLO1 enzyme activity and protein 
expression in 12 months old WT and nRKO mice.  
(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-
month-old WT and nRKO mice (n=4-5/group) in time-dependent manner [Two-way ANOVA, 
genotype: F (1, 35) = 257.1,  time:  F (4, 35) = 13.55, interaction: F (4, 35) = 0.2272, P<0.001]. 
(B) GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands 
of GLO1 in the brain homogenates from indicated mice (n=4-5/group). Representative 
immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as 
loading control. (C) Quantification of GLO1 immunoreactive bands was performed for blots in 











































































Figure 5: Effect of neuronal DNRAGE on GLO1 enzyme activity and protein expression in 
12 months old WT and neuronal DNRAGE mice.  
(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-
month-old WT and neuronal DNRAGE mice (n=3-6/group) in time-dependent manner (Two-way 
ANOVA, time: F (4, 50) = 0.01678,  genotype: F (1, 50) = 89.30, interaction: F (4, 50) = 0.05961, 
P=0.0039). (B)GLO1 protein expression was demonstrated by quantifying intensity of 
immunoreactive bands of GLO1 in the brain homogenates from indicated mice (n=4-5/group). 
Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin 
protein used as loading control. (C) Quantification of GLO1 immunoreactive bands was performed 












































































Figure 6: Effect of DNMSR mutant on GLO1 enzyme activity and protein expression in 12 
months old WT and DNMSR mice.  
(A)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 12-
month-old WT and DNMSR mice (n=4/group) in time-dependent manner (Two-way ANOVA, 
time: F (4, 16) = 36.85, genotype: F (1, 4) = 74.33, interaction: F (4, 16) = 6.103, P<0.0001). 
(B)GLO1 protein expression was demonstrated by quantifying intensity of immunoreactive bands 
of GLO1 in the brain homogenates from indicated mice (n=4-5/group). Representative 
immunoblots show immunoreactive bands for GLO1(21kda) as well as β-Actin protein used as 
loading control. (C) Quantification of GLO1 immunoreactive bands was performed for blots in 































✱✱   ✱✱✱✱   
✱✱  



























































Figure 7: Effect of presence of mutant APP on GLO1 enzyme activity and protein expression 
in 12 months old WT, APP, APP/RO and RO mice.  
(a)GLO1 enzyme activity was determined by spectrophotometric method in the cortex from 
indicated four genotypes of mice (n=5/group, age=12-15 months) in time-dependent manner [two-
way ANOVA, genotype: F (2, 3) = 163.1, time: F (3, 12) = 266.9, interaction: F (8, 12) = 0.5848, 
p<0.0001]. (b)GLO1 protein expression was demonstrated by quantifying intensity of 
immunoreactive bands of GLO1 in the brain homogenates from indicated mice. (n=4-5/group). 
Representative immunoblots show immunoreactive bands for GLO1(21kda) as well as β-actin 
protein used as loading control. (c) quantification of GLO1 immunoreactive bands was performed 
for blots in triplicate (one-way ANOVA, Tukey’s multiple comparison test, F (3, 4) = 109.5, 









RAGE, a receptor for AGEs, is an immunoglobulin like cell surface receptor that is described as a 
pattern recognition receptor[3, 51, 55, 151]. RAGE is an important cellular co-factor for Aβ-
mediated cellular changes relevant in pathogenesis of Alzheimer’s disease. Interaction of RAGE 
with Aβ in neurons, microglia and vascular cells accelerates and exaggerates the detrimental effect 
on neuronal and synaptic function[42, 59, 81, 152]. RAGE-dependent signaling contributes to Aβ-
mediated amyloid pathology and cognitive dysfunction observed in AD mouse model[3, 14, 28, 
73, 85, 153-157]. On the other hand, RAGE deletion significantly attenuates neuronal and synaptic 
injury as previously shown[3, 28, 48]. RAGE inhibitors have been described previously to mitigate 
symptoms of AD[42, 57, 70, 158-160] and are found to be safe and effective orally in phase II 
clinical trials of AD[161].  
 
MG is a major precursor of AGESs. As a metabolic byproduct continuously generated in vivo, 
MG can directly induce apoptosis[162-165] by generating oxidative stress. Moreover, MG is also 
found to be involved in the formation of Aβ and NFTs in AD[24, 31, 69, 166-173]. Furthermore, 
it is suggested that the decline in cognitive function in AD patients is closely related to the MG 
level as well as to the change in the glyoxalase system level or activity[23, 116, 122, 128, 174]. 
As one of the most important enzyme systems in vivo, the glyoxalase system exhibits 
detoxification of α-ketoaldehydes or dicarbonyl compounds including MG and glyoxal. However, 
the direct association between GLO1 and AD pathology still needed further exploration. Though 
various important signaling pathways possibly contribute to AD pathogenesis, here we focused 




Thus, the current study was designed to evaluate whether global deletion of RAGE along with the 
RAGE signaling blockade would have protective effects against changes in the GLO1 activity and 
protein expression due to AGEs-mediated disturbances and mAPP.  
 
GLO1 enzyme activity is dependent on RAGE and is modulated in age-dependent manner. 
 
Aging is characterized by physiological and functional deterioration across multiple organ 
systems. AGEs are found in abundance in the serum and accumulate in the tissues during normal 
aging. This accumulation is accelerated in pathological conditions such as diabetes and 
neurodegenerative diseases, such as AD[23, 59, 175]. Diabetes has been known to be a contributor 
to AD pathology[176, 177]. Increased levels of AGEs are reported in the cortical neurons of older 
adults and are linked to the severity of cognition impairment. The serum AGE levels are 
significantly increased in diabetic patients compared to healthy, non-diabetic controls. AGE-
induced cellular perturbation and oxidative stress were blocked by antibodies to RAGE[178, 179]. 
Thus, increased levels of AGEs and RAGE play an important role in AGE-mediated cellular 
disturbances during the pathogenesis of aging-related disorders and diabetes.  
 
To investigate the effects of physiological aging on GLO1 activity, we carried out an initial study 
in the WT mice of different ages. It is well supported in the literature that with increasing age, 
there is a consistent increase in the AGE levels which lead to RAGE-mediated changes in neuronal 
function which should lead to decrease in GLO1 activity according to our hypothesis [27, 100, 
175, 180]. Corroborating that, we found significant decrease in the GLO1 activity of older WT 




months till the age of 12 months[100, 101] but beyond that, there was a significant reduction in 
GLO1 activity seen in 20- and 30-month old mice. These results support the minor elevation in 
GLO1 levels observed in young mice as reported in the previous literature[100, 101, 130]. Based 
on these preliminary studies, we used approximately 12-month-old mice for further comparative 
studies for uniformity and to remove the confounding factor of age.  
 
Further, we wanted to look at the direct effect of genetic deletion of RAGE. Thus, we used 
previously generated RO mice. The spectrophotometric measurement of GLO1 enzyme activity 
revealed significantly increased GLO1 activity in RO mice compared with WT mice at 6 months 
and 12 months. In 12-month-old mice, the protein levels were significantly increased in RO mice 
compared with those of 12-month-old WT mice. But this effect was not observed in 6 months old 
mice. This difference in the effect can possibly be explained by the dissimilar changes seen in 
GLO1 levels in animals of different ages as found in the preliminary experiments in aging WT 
mice. This could be the effect of age on RAGE-modulated GLO1 expression and function. 
 
RAGE is required both in neurons and microglia for regulating GLO1 activity.  
 
Since RAGE is expressed in both neuronal and non-neuronal cells[14, 20, 27, 48, 54, 68, 69, 75, 
80], the results from RO mice did not differentiate if the effect was due to a specific type of cell.  
Here, we wanted to look at the direct effect of other genetic manipulation of RAGE (conditional 
deletion or signaling blockade). Thus, we used two different previously generated transgenic 
mouse models: nRKO mouse model and DNMSR mouse model, to address the question of whether 





We studied GLO1 activity and protein levels in these nRKO and DNMSR mice. These experiments 
revealed significantly increased GLO1 activity in the brains of both nRKO and DNMSR mice 
compared with age-matched WT control mice. The protein levels were slightly increased 
compared with those of WT mice, but the change was not statistically significant. 
These results showed that absence of RAGE in both types of cells resulted in similar effect 
indicating that RAGE is required in both neuronal and microglial cells to modulate GLO1 activity. 
But these similar results do not necessarily point to a similar signaling mechanism. 
 
Use of both global and neuronal knockout mice differs from cell-type specific DNRAGE mice. In 
case of DNRAGE mice, only the cytosolic tail is absent from the receptor leading to loss of 
signaling whereas for RAGE knockout mice, there is complete absence of receptor from the cell 
membrane. Thus, in case of DNRAGE mice, the receptor is available to bind ligands and modify 
them and reduce the unbound ligands from the extracellular fluid. That is not the case for knockout 
mice. Also, dimerization of RAGE is thought to be key for its signaling and other biological 
effects[181, 182], which is not possible in case of RAGE knockout.  
 
To address this issue if the results seen in DNRAGE mice are due to sequestration of ligands 
(which is not possible in knockout mice), we further used neuronal DNRAGE mice. We found that 
neuronal DNRAGE mutation significantly upregulated GLO1 activity but did not alter protein 
expression, which is similar to the effect seen in earlier 2 models (nRKO and DNMSR).  There 
were anomalies seen in the protein levels from western blot. Since the trend observed was of an 




experiments to confirm the results. From these observations, we concluded that the effect in 
DNRAGE is not due to the difference between sequestration of ligands with the receptor. These 
results also show that the mechanism by which RAGE affects GLO1 activity and expression is 
similar for both types of cells. So, RAGE is an important modulator of GLO1 regardless of the cell 
type. 
 
GLO1 protein levels are not altered in mice with cell-type specific RAGE mutations.  
 
From the above experiments, we found that though RAGE deletion or DNRAGE leads to increased 
GLO1 enzyme activity in both global knockout and other 3 models, the protein levels are affected 
differently.  
This difference can possibly be explained by various factors such as: 
a) Difference in post-translational modification (PTM). GLO1 undergoes 4 different types of 
modifications namely (i) removal of the n-terminal methionine 1, (ii) n-terminal acetylation 
at alanine 2, (iii) a vicinal disulfide bridge between cysteine residues 19 and 20, and (iv) a 
mixed disulfide bond formed by reaction between thiolate of glutathione and disulfide bond 
of cysteine 139. MG also leads to PTM of proteins. Disulfide bridge formation impacts the 
enzyme activity while not impacting protein levels or enzyme stability. Different genotypes 
will possibly express different PTMs. So, if this particular modification i.e. disulfide bond 
formation occurs in the genotype, then it might be the reason of the higher enzyme activity 
but no change in protein levels[183].  
b) Inherently, there can be differences in the conformation of the enzyme which may lead to 




of protein denaturation where the protein loses its function, which might lead to the protein 
levels to be lower or different. Since, the WT and Tg mice have similar conformation 
(being littermates), it possibly leads to insignificant difference/changes in protein levels. 
c) For all the experiments, brain cortex homogenate was used. Thus, the homogenate 
contained both neuronal and non-neuronal cells. For cell-type specific mutants, some of 
the other cells in the homogenate without the knockout carried the intact RAGE exerting 
its effect, thus incomplete RAGE suppression may occur. This can possibly lead to no 
significant increase in the protein levels unlike the clear increase seen in the case of 
complete knockout models (RO and APP/RO).  
d) In a yeast Schizosaccharomyces pombe, GLO1 activity is regulated in response to osmotic 
stress. But there is no change in mRNA or protein levels. This can be the case in 
mammalian GLO1 modulation as well[184]. In case of the experimental mice, different 
genotypes (WT and Tg) will experience different levels of osmotic stress which will cause 
enzyme activity to change but it might not affect the protein levels. 
e) MG induces protein modification such as glycation which causes partial unfolding and 
thus, forms unstable proteins which degrade over time. This denaturation may cause non-
significant differential change in the protein levels[185, 186]. Different degrees of 
denaturation might occur in animals based on gender and genotype. This will lead to 
differential influence on the protein levels. This might be the reason why we saw a variable 
degree of change in protein levels across multiple animal models. 
f) The methods used such as enzyme activity assay and western blotting have different 
sensitivity to the GLO1 protein levels or activity measured during the experiments. In case 




sample. In enzyme activity assay, the change in the OD measured tells us about the rate at 
which the enzyme reacts with the substrate and converts it to the product. In enzyme 
activity, the substrate binds to the enzyme leading to a signaling cascade which leads to 
signal amplification. This might be the main reason for the differences seen between the 
two methods, where we saw an increase in enzyme activity but no significant change in 
protein levels.  
g) Gender differences and other variability among the mice. In literature, it has been found 
that there are sex differences in brain function, molecular changes and neurogenesis. Since 
our study included both male and female mice in different numbers (for each group), it is 
possible that the cumulative gender difference plays a role in the differential effect on 
protein expression [187]. It is also possible that an animal expresses higher or lower amount 
of protein leading to the different result. 
 
APP mutation regulates GLO1 activity and protein level through RAGE signaling. 
 
Amyloid plaques are characteristic lesions found in Alzheimer’s disease (AD) and are composed 
of Aβ derived from APP [188]. Aβ formation involves sequential proteolytic cleavage of APP by  
β and γ-secretases [189-192]. β -secretase mediates APP cleavage to form the amino (N)-terminus 
of Aβ and yields the membrane bound C-terminal fragment CTFβ [190]. Next, γ-secretase cleaves 
CTFβ to release Aβ peptide and APP intracellular C-terminal domain (AICD), a 6-KD peptide also 





AGE accumulation has been demonstrated in senile plaques in different cortical areas such as 
entorhinal cortex[20, 75] and glial cells of AD brain [193]. We have previously published about 
RAGE-mediated Aβ accumulation in a mouse model of AD which was via modulation of β and γ-
secretase activity through activation of GSK3β and P38 MAP kinase[28]. It has been demonstrated 
in vitro that aggregation of Aβ is significantly accelerated by AGE-mediated crosslinking[194]. 
Thus, AGEs may be one of the factors which accelerate Aβ deposition and plaque formation in 
AD[195]. 
 
Our previous studies demonstrated that increased cellular RAGE causes more Aβ-mediated 
perturbation in patients with AD and in an AD mouse model[3, 11, 13, 28, 155, 196, 197]. The 
literature mentions RAGE-dependent signaling in microglia contributes to neuroinflammation [74, 
75]. However, deletion or selective deficiency of neuronal or microglial RAGE signaling by 
DNRAGE in the AD mouse model attenuated deterioration induced by AGEs or mAPP[21, 28]. It 
was also found that blockade of microglial RAGE is beneficial for Aβ-mediated neuronal changes 
[20, 69, 73]. 
 
We sought to study whether RAGE had a direct role in modulating GLO1 activity and expression 
in mAPP mice overexpressing mutant APP/Aβ (mAPP). We also determined the effect of deletion 
of RAGE in these mice(mAPP/RO). Tg mAPP (Swedish mutation: APP KM670/671NL, V717F) 
mouse model is a well-established animal model for AD.  We demonstrated that GLO1 activity 
and protein levels were significantly reduced in homozygous mAPP mice compared with WT 
mice. In contrast, GLO1 activity was found to be higher in both heterozygous mAPP/RO and 




mice show that RAGE deletion has a protective effect against the downregulation of GLO1 activity 
seen in mAPP mice. Consistent with the enzyme activity results, the protein levels were also 
increased in both mAPP/RO and RO mice compared with those of 12-months-old mAPP mice.  
 
Here, due to the presence of mutant APP in case of mAPP mice, the activity and protein levels 
decreased compared to WT controls. This mutation leads to overexpression of APP, which in turn 
leads to accelerated formation of Aβ. This Aβ formation causes plaque formation with increasing 
age. Since Aβ is known to bind to RAGE[14, 67, 151], this interaction causes RAGE-mediated 
signaling which leads to decrease in the GLO1 activity. In contrast, due to global knockout in RO 
and mAPP/RO mice, the activity and protein levels both showed significant improvement 
compared to mAPP mice. Thus, we concluded that global deletion of RAGE in mAPP/RO mice 
rescued the decrease in GLO1 activity and expression seen in mAPP mice. 
 
Possible mechanism for effect of AGEs-RAGE interaction on GLO1 activity can be through 
multiple pathways such as formation of reactive oxygen species (ROS) leading to oxidative stress, 
activation of PI3K-AKT pathway [76] and stimulation of P38 or ERK signaling[66]. All these 
activations lead to upregulation of NF-қB, which is known to be involved in inflammation, DNA 
transcription and cytokine production[81, 106]. This NF-қB upregulation leads to pro-
inflammatory cytokine release causing neuroinflammation, which is one of the major changes seen 
in case of AD. It has also been reported that NF-қB regulates APP and β and γ-secretases[198]. 





So, to summarize, enzyme activity assay and western blot analysis indicated that in comparison to 
healthy controls, GLO1 activity and protein levels decreased with age and in the presence of mAPP 
expression. In transgenic non-AD models where RAGE was deleted or signaling was blocked, 
GLO1 enzyme activity increased though there was variable effect regarding the GLO1 protein 
levels possibly due to various factors discussed above.  
 
The data presented herein clearly demonstrates, that genetic deletion of RAGE or loss of RAGE 
signaling significantly increased GLO1 activity in the four transgenic and mAPP mouse models. 
The GLO1 protein expression also increased in case of RO and mAPP/RO mice. Using our novel 
transgenic mouse models with RAGE deletion or conditional DNRAGE mutant for this evaluation, 
we provide convincing evidence to support the effects of AGEs–RAGE interaction on GLO1 
enzyme activity and protein expression.  
 
Our findings also suggest that RAGE is a strong potential target to limit AGEs-induced 
perturbations, which is in accordance with previous literature [3, 19, 28, 63, 72, 73, 79, 82, 153, 
199, 200]. Also, the decrease of GLO1 expression with increasing age and pathology might be one 
reason for AGE or MG-induced neuronal impairment, apoptosis, and AGE formation in plaques 
and NFTs seen in AD. Thus, GLO1 appears to be an important enzyme target for protection against 
RAGE-mediated signaling[140, 201, 202]. So, restoring or enhancing GLO1 activity can provide 






Several strategies, to prevent the AGEs-induced disturbances, are described in literature such as 
enhancement of GLO1 activity[108, 112, 114, 118, 119, 132-134, 203, 204], use of RAGE 
inhibitors  [11, 57, 61, 124, 127, 160, 200, 205], inhibition of MG toxic reactions by using AGE 
antagonists[23, 127] which are antioxidants[133, 206] and decreasing glycation activity by using 
anti-diabetic drugs[16, 207-211]. All these approaches lead to direct or indirect enhancement or 
restoration of GLO1 activity. They are also efficient in alleviating some AD symptoms such as 
cognitive impairment and neuroinflammation.  
 
Our study was a simple attempt at correlating certain factors such as RAGE in AD to the MG-
detoxification process in the brain through the glyoxalase system. There are certain limitations to 
our studies because it may not be possible to always extrapolate animal data to humans since 
animal models are not a perfect predictor of human physiological or pathological conditions. There 
also needs to be a further extensive study in clinical settings as well as other animal models to have 
a better in vivo-in vitro correlation. We need a detailed study of significance of GLO1 enzyme 
activity using GLO1 genetic manipulations such as mice exhibiting GLO1 knockout or GLO1 
overexpression [126]. 
 
To conclude, we show that GLO1 is directly upregulated by RAGE deletion or signaling blockade 
but the exact role of glyoxalase system in the AD pathogenesis and involved signaling pathways 
such as MAPK need further investigation. Also, GLO1 is downregulated in case of mAPP 
mutation featuring overproduction of Aβ. Blockade of AGEs-RAGE axis by genetic deletion of 
RAGE and by use of DNRAGE protects against this downregulation of GLO1 activity and further 




Thus, it will be very crucial and valuable to further study the significance of glyoxalase system 
which will contribute to a better understanding of AD pathogenesis, as well as find new therapies 
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